Nucleic acid amplification tests for HIV, HBV, and HCV in tissue donors: Useful or dispensable?;Nukleinsäure-amplifikationstests für HIV, HBV und HCV bei gewebespendern: Sinnvoll oder überflüssig?

Transfusion Medicine and Hemotherapy

Volumn 35, Issue 6, 2008, Pages 421-430

  Pruß, Axel ^a,c   Caspari, Gregor ^b   Krüger, Detlev H ^c   Blümel, Johannes ^d   Nübling, C Micha ^d   Quenzel, Ernst Markus ^e   Kalus, Ulrich ^a   Gerlich, Wolfram ^f   Gürtler, Lutz ^g  

^a Gewebebank   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d PAUL EHRLICH INSTITUT   (Germany)

^e Institut für Transfusionsmedizin

^f JUSTUS LIEBIG UNIVERSITY   (Germany)

^g UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Allograft; HBV; HCV; HIV; Nucleic acid testing; Tissue bank; Virus safety

Indexed keywords

HEPATITIS B CORE ANTIBODY; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY;

BLOOD DONOR; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS C; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NUCLEIC ACID AMPLIFICATION; PRACTICE GUIDELINE; REVIEW; SEROLOGY; TREPONEMA PALLIDUM HEMAGGLUTINATION TEST; VIRUS DETECTION; VIRUS TRANSMISSION;

EID: 57449107060     PISSN: 16603796     EISSN: None     Source Type: Journal    
DOI: 10.1159/000165779     Document Type: Review

References (51)

1. Bundesärztekammer: Richtlinien zum Führen einer Knochenbank. Dtsch Arztebl 2001;98:A1011-1016.
2. Bundesärztekammer: Richtlinien zum Führen einer Hornhautbank. Dtsch Arztebl 2000;97:A2122-2124.
3. Paul-Ehrlich-Institut: Bekanntmachung über die Ergebnisse des Stufenplanverfahrens zur Verminderung des Risikos von Hepatitis B-, Hepatitis Cund HIV-Infektionen bei Empfängern von Erythrozytenkonzentraten vom 25,02 1998. Bundesanzeiger 1998;63:4477.
4. Paul-Ehrlich-Institut: Abwehr von Arzneimittelrisiken: Verminderung des Risikos von Hepatitis CVirus-Kontaminationen in Thrombozytenkonzentraten vom 05,06 1998. Bundesanzeiger 1998;114:8775.
5. Busch MP, Kleinman SH, Jackson B, Stramer SL, Hewlett I, Preston S: Committee report. Nucleic acid amplification testing of blood donors for transfusion-transmitted infectious diseases: Report of the Interorganizational Task Force on Nucleic Acid Amplification Testing of Blood Donors. Transfusion 2000;40:143-159.
6. Paul-Ehrlich Institut: Verminderung des Risikos von HIV-1-Infektionen durch zelluläre Blutprodukte und gefrorenes Frischplasma - Anordnung der Testung auf HIV-1-RNA mit NAT. Bundesanzeiger 2003;103:12269.
7. Hourfar MK, Jork, C, Schottstedt V, Weber-Schehl M, Brixner V, Busch MP, Geusendam G, Gubbe K, Mahnhardt C, Mayr-Wohlfart U, Pichl L, Roth WK, Schmidt M, Seifried E, Wright DJ: Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus. Transfusion 2008;48:1541-1544.
8. Paul-Ehrlich-Institut: Abwehr von Arzneimittelrisiken; Testung auf Antikörper gegen Hepatitis-B-Core-Antigen (anti-HBc) im Blutspendewesen. Bundesanzeiger 2006;109:4370.
9. Busch MP: Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors? Transfus Clin Biol 2004;11:26-32.
10. Stramer SL, Glynn SA, Kleinman SH, Strong DM, Caglioti S, Wright DJ, Dodd RY, Busch MP: Detection of HIV-1 and HCV infections among antibody-negative blood donors by nucleic acid-amplification testing. N Eng J Med 2004;351:760-768.
11. Offergeld R, Ritter S, Hamouda O: HIV, HCV, HBV and syphilis infections among blood donors in Germany 2005. Bundesgesundheitsbl Gesundheitforsch Gesundheitsschutz 2007;50:1221-1231.
12. Nübling CM, Unkelbach U, Chudy M, Seitz R: Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools. Transfusion 2008;48:822-826.
13. Paul-Ehrlich-Institut: Anforderungen an die diagnostische Erprobung von NAT zum Nachweis, zur Bestätigung und zur quantitativen Bestimmung von Markern von HIV-Infektionen sowie von Hepatitis B und C in Proben menschlichen Ursprungs. Bundesanzeiger 2000;213:21805.
14. Challine D, Pellegrin B, Bouvier-Alias M, Rigot P, Laperche L, Pawlotsky JM: HIV and hepatitis C virus RNA in seronegative organ and tissue donors. Lancet 2004;364:1611-1612.
15. Zou S, Dodd RY, Stramer SL, Strong DM; Tissue Safety Study Group: Probability of viremia with HBV, HCV, HIV, and HTLV among tissue donors in the United States. N Engl J Med 2004;351:751-759.
16. Yao F, Seed C, Farrugia A, Morgan D, Cordner S, Wood D, Zheng MH: The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia. Am J Transplant 2007;7:2723-2726.
17. Challine D, Roudot-Thoraval F, Sabatier P, Dubernet F, Larderie P, Rigot P, Pawlotsky JM: Serological viral testing of cadaveric cornea donors. Transplantation 2006;82:788-793.
18. Heim A, Wagner D, Rothämel T, Hartmann U, Flik J, Verhagen W: Evaluation of serological screening of cadaveric sera for donor selection for cornea transplantation. J Med Virol 1999;58:291-295.
19. Strong DM, Nelson K, Pierce M, Stramer SL: Preventing disease transmission by deceased tissue donors by testing blood for viral nucleic acid. Cell Tiss Bank 2005;6:255-262.
20. Schratt HE, Regel G, Kiesewetter B, Tscherne H: HIV-Infektion durch kältekonservierte Knochentransplantate. Unfallchirurg 1996;9:679-684.
21. CDC, Centers for Disease Control and Prevention: Transmission of HIV through bone transplantation: case report and public health recommendations. MMWR 1988;37:597-599.
22. Simonds RJ, Holmberg SD, Hurwitz RL, Coleman TR, Bottenfield S, Conley LJ, Kohlenberg SH, Castro KG, Dahan BA, Schable CA: Transmission of human immunodeficiency virus type 1 from a seronegative organ and tissue donor. N Engl J Med 1992;326:726-732.
23. Clarke JA: HIV transmission and skin grafts. Lancet 1987;i:983.
24. Li CM, Ho YR, Liu YC: Transmission of human immunodeficiency virus through bone transplantation: A case report. J Formosan Med Assoc 2001;100:350-351.
25. Conrad EU, Gretch DR, Obermeyer KR, Moogk MS, Sayers M, Wilson JJ, Strong DM: Transmission of the hepatitis-C virus by tissue transplantation. J Bone Joint Surg Am 1995;77:214-224.
26. Eggen BM, Nordbo SA: Transmission of HCV by organ transplantation. N Engl J Med 1992;326:411.
27. Pereira BJ, Milford EL, Kirkman RL, Levey AS, Tomford WW, Leibowitz H, Rhodes M, Quan S, Wilbur JC: Low risk of liver disease after tissue transplantation from donors with HCV. Lancet 1993;341:903-904.
28. Tugwell BD, Patel PR, Williams IT, Hedberg K, Chai F, Nainan OV, Thomas AR, Woll JE, Bell BP, Cieslak PR: Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor. Ann Intern Med 2005;143:648-654.
29. Shutkin NM: Homologous-serum hepatitis following the use of refrigerated bone-bank bone. J Bone Joint Surg 1954;36A:160-162.
30. Marthy S, Richter M: Human immunodeficiency virus activity in rib allografts. J Oral Maxillofac Surg 1998;56:474-476.
31. Cook SD, Salkeld SL, Prewett AB: Simian immunodeficiency virus (human HIV-II) transmission in allograft bone procedures. Spine 1995;20:1338-1342.
32. CDC, Centers for Disease Control and Prevention: Update: allograft-associated bacterial infections. MMWR 2002;51:207-210.
33. Hoft RH, Pflugfelder SC, Forster RK, Ullman S, Polack FM, Schiff ER: Clinical evidence for hepatitis B transmission resulting from corneal transplantation. Cornea 1997;16:132-137.
34. Morris A, Strickett MG, Barratt-Boyes BG: Use of aortic valve allografts from hepatitis B surface antigen-positive donors. Ann Thorac Surg 1990;49:802-805.
35. Schwarz A, Hoffman F, L'Age Stehr J, Tegzess AM, Offermann G: Human immunodeficiency virus transmission by organ donation: Outcome in cornea and kidney recipients. Transplantation 1987;44:21-24.
36. Krajden M, Bishai F, Quan C, Mahony J, Brunton J, Rootman D, Zhao J, Lau W, Snell G, Maurer J, Kesten S, Colby D: Multi-organ donor transmission of hepatitis C virus to five solid organ transplant recipients and lack of transmission to corneal transplant recipients. Clin Diagn Virol 1995;3:113-121.
37. Caron MJ, Wilson R: Review of the risk of HIV infection through corneal transplantation in the United States. J Am Optom Assoc 1994;65:173-178.
38. Sengler V, Reinhard T, Adams O, Gerlich W, Sundmacher R: Testing of corneoscleral discs and their culture media of seropositive donors for hepatitis B and C virus genomes. Graefes Arch Clin Exper Ophthalmol 2001;239:783-787.
39. Lee HM, Naor J, Alhindi R, Chinfook T, Krajden M, Mazzulli T, Rootman DS: Detection of hepatitis C virus in the corneas of seropositive donors. Cornea 2001;20:37-40.
40. Glasser DB: Serologic testing of cornea donors. Cornea 1998;17:123-128.
41. Robert PY, Adenis JP, Pleyer U: How 'safe' is corneal transplantation? A contribution on the risk of HSV-transmission due to corneal transplantation. Klin Monatsbl Augenheilkd 2005;222:870-873.
42. Thuret G, Acquart S, Gain P, Thuret G, Dumollard JM, Manissolle C, Campos-Guyotat L, Gain P, Labetoulle M, Bourlet T: Ultrastructural demonstration of replicative herpes simplex virus type 1 transmission through corneal graft. Transplantation 2004;77:325-326.
43. Bronnert J, Wilde H, Tepsumethanon V, Lumlertdacha B, Hemachudha T: Organ transplantations and rabies transmission. J Travel Med 2007;14:177-180.
44. Maddox RA, Belay ED, Curns AT, Zou WQ, Nowicki S, Lembach RG, Geschwind MD, Haman A, Shinozaki N, Nakamura Y, Borer MJ, Schonberger LB: Creutzfeldt-Jakob disease in recipients of corneal transplants. Cornea 2008;27:851-854.
45. Donoso Mantke O, Meyer R, Prösch S, Nitsche A, Leitmeyer K, Kallies R, Niedrig M: High prevalence of cardiotropic viruses in myocardial tissue from explanted hearts of heart transplant recipients and heart donors: a 3-year retrospective study from a German patients' pool. J Heart Lung Transplant 2005;24:1632-1638.
46. Pruss A, Katthagen BD: Musculoskeletal tissue banks: Legal foundations and graft safety. Orthopäde 2008;37:749-755.
47. Uhlenhaut C, Dörner T, Pauli G, Pruss A: Effects of lyophilization on the infectivity of enveloped and non-enveloped viruses in bone tissue. Biomaterials 2005;26:6558-6564.
48. Nübling CM, Unger G, Chudy M, Raia S, Löwer J: Sensitivity of HCV core antigen and RNA detection in the early infection phase. Transfusion 2002;42:1037-1045.
49. Tuke PW, Grant PR, Waite J, Kitchen AD, Eglin RP, Tedder RS: Hepatitis C virus window-phase infections: closing the window on hepatitis C virus. Transfusion 2008;48:594-600.
50. Komiya Y, Katayama K, Yugi H, Mizui M, Matsukura H, Tomoguri T, Miyakawa Y, Tabuchi A, Tanaka J, Yoshizawa H: Minimum infectious dose of hepatitis B virus in chimpanzees and difference in the dynamics of viremia between genotype A and genotype C. Transfusion 2008;48:286-294.
51. Österreichisches Bundesinstitut für Gesundheitswesen (ÖBIG) und Bundesministerium für soziale Sicherheit und Generationen: Richtlinien für Homograft-Banken. ÖBIG, April 2002.